With orphan drugs typically being high value, the potential risk of stock losses should be a top concern for biotechs looking ...

The European orphan drug market is growing and is already comparable in size and scope to the US market. The European Union ...

The European market for orphan drugs presents many opportunities and challenges for pharma companies. With over 30 million people in the EU living with rare diseases, the demand for innovative ...

The results show that HTAs for orphan drugs can vary widely across Europe, causing inconsistencies in evidence requirements and recommendations. The study reviewed all 80 European Medicines Agency ...

and the E.U.’s European Medicines Agency (EMA). “The granting of Orphan Drug Designation in these two jurisdictions confirms that we are on a relatively rapid and cost-effective path to market ...